


UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.



1. Issuer's Identity

CIK (Filer ID Number) 0000822370 Previous Name(s) MYnd Analytics, Inc. Entity Type Corporation Name of Issuer CNS RESPONSE, INC. Emmaus Life Sciences, Inc. STRATIVATION, INC. Jurisdiction of Incorporation/Organization DELAWARE Year of Incorporation/Organization Over Five Years Ago

2. Principal Place of Business and Contact Information

Name of Issuer Emmaus Life Sciences, Inc. Street Address 1 21250 HAWTHORNE BLVD. Street Address 2 SUITE 800 City TORRANCE State/Province/Country CALIFORNIA ZIP/Postal Code 90503 Phone No. of Issuer 310-214-0065

3. Related Persons

Last Name Nihara First Name Yutaka Middle Name Street Address 1 21250 Hawthorne Blvd. Street Address 2 Suite 800 City Torrance State/Province/Country CALIFORNIA ZIP/Postal Code 90503 Relationship: Executive Officer Director Promoter Clarification of Response (if Necessary) Chairman and Chief Executive Officer

Last Name Lee First Name Willis Middle Name Street Address 1 21250 Hawthorne Blvd. Street Address 2 Suite 800 City Torrance State/Province/Country CALIFORNIA ZIP/Postal Code 90503

Relationship:	<input checked="" type="checkbox"/> Executive Officer	<input checked="" type="checkbox"/> Director	<input type="checkbox"/> Promoter
---------------	---	--	-----------------------------------

Clarification of Response (if Necessary)

Chief Operating Officer

Last Name	First Name	Middle Name
<input type="text" value="Nagasaki"/>	<input type="text" value="Yasushi"/>	
Street Address 1	Street Address 2	
<input type="text" value="21250 Hawthorne Blvd."/>	<input type="text" value="Suite 800"/>	
City	State/Province/Country	ZIP/Postal Code
<input type="text" value="Torrance"/>	<input type="text" value="CALIFORNIA"/>	<input type="text" value="90503"/>

Relationship:	<input checked="" type="checkbox"/> Executive Officer	<input type="checkbox"/> Director	<input type="checkbox"/> Promoter
---------------	---	-----------------------------------	-----------------------------------

Clarification of Response (if Necessary)

Chief Financial Officer

Last Name	First Name	Middle Name
<input type="text" value="Sekulich"/>	<input type="text" value="George"/>	
Street Address 1	Street Address 2	
<input type="text" value="21250 Hawthorne Blvd."/>	<input type="text" value="Suite 800"/>	
City	State/Province/Country	ZIP/Postal Code
<input type="text" value="Torrance"/>	<input type="text" value="CALIFORNIA"/>	<input type="text" value="90503"/>

Relationship:	<input checked="" type="checkbox"/> Executive Officer	<input type="checkbox"/> Director	<input type="checkbox"/> Promoter
---------------	---	-----------------------------------	-----------------------------------

Clarification of Response (if Necessary)

Senior Vice President Global Commercialization and Chief Information Officer
--

Last Name	First Name	Middle Name
<input type="text" value="Stark"/>	<input type="text" value="Charles"/>	
Street Address 1	Street Address 2	
<input type="text" value="21250 Hawthorne Blvd."/>	<input type="text" value="Suite 800"/>	
City	State/Province/Country	ZIP/Postal Code
<input type="text" value="Torrance"/>	<input type="text" value="CALIFORNIA"/>	<input type="text" value="90503"/>

Relationship:	<input checked="" type="checkbox"/> Executive Officer	<input type="checkbox"/> Director	<input type="checkbox"/> Promoter
---------------	---	-----------------------------------	-----------------------------------

Clarification of Response (if Necessary)

Senior Vice President of Medical Affairs
--

Last Name	First Name	Middle Name
<input type="text" value="Seah"/>	<input type="text" value="Lim"/>	
Street Address 1	Street Address 2	
<input type="text" value="21250 Hawthorne Blvd."/>	<input type="text" value="Suite 800"/>	
City	State/Province/Country	ZIP/Postal Code
<input type="text" value="Torrance"/>	<input type="text" value="CALIFORNIA"/>	<input type="text" value="90503"/>

Relationship:	<input type="checkbox"/> Executive Officer	<input checked="" type="checkbox"/> Director	<input type="checkbox"/> Promoter
----------------------	--	--	-----------------------------------

Clarification of Response (if Necessary)

Last Name	First Name	Middle Name
Zwicker	Ian	
Street Address 1	Street Address 2	
21250 Hawthorne Blvd.	Suite 800	
City	State/Province/Country	ZIP/Postal Code
Torrance	CALIFORNIA	90503

Relationship:	<input type="checkbox"/> Executive Officer	<input checked="" type="checkbox"/> Director	<input type="checkbox"/> Promoter
----------------------	--	--	-----------------------------------

Clarification of Response (if Necessary)

Last Name	First Name	Middle Name
Zen	Wei Peu (Derek)	
Street Address 1	Street Address 2	
21250 Hawthorne Blvd.	Suite 800	
City	State/Province/Country	ZIP/Postal Code
Torrance	CALIFORNIA	90503

Relationship:	<input type="checkbox"/> Executive Officer	<input checked="" type="checkbox"/> Director	<input type="checkbox"/> Promoter
----------------------	--	--	-----------------------------------

Clarification of Response (if Necessary)

4. Industry Group

- Agriculture
- Banking & Financial Services**
 - Commercial Banking
 - Insurance
 - Investing
 - Investment Banking
 - Pooled Investment Fund
 - Other Banking & Financial Services
- Business Services**
 - Energy**
 - Coal Mining
 - Electric Utilities
 - Energy Conservation
 - Environmental Services
 - Oil & Gas
 - Other Energy
- Health Care**
 - Biotechnology
 - Health Insurance
 - Hospitals & Physicians
 - Pharmaceuticals
 - Other Health Care
- Manufacturing**
- Real Estate**
 - Commercial
 - Construction
 - REITS & Finance
 - Residential
 - Other Real Estate
- Retailing**
- Restaurants**
- Technology**
 - Computers
 - Telecommunications
 - Other Technology
- Travel**
 - Airlines & Airports
 - Lodging & Conventions
 - Tourism & Travel Services
 - Other Travel
- Other**

5. Issuer Size

- | | |
|---|--|
| Revenue Range | Aggregate Net Asset Value Range |
| <input type="radio"/> No Revenues | <input type="radio"/> No Aggregate Net Asset Value |
| <input type="radio"/> \$1 - \$1,000,000 | <input type="radio"/> \$1 - \$5,000,000 |

- | | |
|---|--|
| <input type="radio"/> \$1,000,001 - \$5,000,000 | <input type="radio"/> \$5,000,001 - \$25,000,000 |
| <input checked="" type="radio"/> \$5,000,001 - \$25,000,000 | <input type="radio"/> \$25,000,001 - \$50,000,000 |
| <input type="radio"/> \$25,000,001 - \$100,000,000 | <input type="radio"/> \$50,000,001 - \$100,000,000 |
| <input type="radio"/> Over \$100,000,000 | <input type="radio"/> Over \$100,000,000 |
| <input type="radio"/> Decline to Disclose | <input type="radio"/> Decline to Disclose |
| <input type="radio"/> Not Applicable | <input type="radio"/> Not Applicable |

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

- | | |
|--|--|
| <input type="checkbox"/> Rule 504(b)(1) (not (i), (ii) or (iii)) | <input checked="" type="checkbox"/> Rule 506(b) |
| <input type="checkbox"/> Rule 504 (b)(1)(f) | <input type="checkbox"/> Rule 506(c) |
| <input type="checkbox"/> Rule 504 (b)(1)(ii) | <input type="checkbox"/> Securities Act Section 4(a) (5) |
| <input type="checkbox"/> Rule 504 (b)(1)(iii) | <input type="checkbox"/> Investment Company Act Section 3(c) |

7. Type of Filing

- New Notice Date of First Sale First Sale Yet to Occur
- Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes No

9. Type(s) of Securities Offered (select all that apply)

- | | |
|--|--|
| <input type="checkbox"/> Pooled Investment Fund Interests | <input type="checkbox"/> Equity |
| <input type="checkbox"/> Tenant-in-Common Securities | <input type="checkbox"/> Debt |
| <input type="checkbox"/> Mineral Property Securities | <input checked="" type="checkbox"/> Option, Warrant or Other Right to Acquire Another Security |
| <input type="checkbox"/> Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security | <input type="checkbox"/> Other (describe) |

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Yes No

Clarification of Response (if Necessary)

11. Minimum Investment

Minimum investment accepted from any outside investor \$ USD

12. Sales Compensation

Recipient	<input type="text" value="none"/>	Recipient CRD Number	<input checked="" type="checkbox"/> None
(Associated) Broker or Dealer	<input checked="" type="checkbox"/> None	(Associated) Broker or Dealer CRD Number	<input checked="" type="checkbox"/> None
<input type="text"/>		<input type="text"/>	

Street Address 1

Street Address 2

NONE

NONE

City

State/Province/Country

ZIP/Postal Code

NONE

Unknown

0000

State(s) of Solicitation

All States

Foreign/Non-US

NEW YORK

13. Offering and Sales Amounts

Total Offering Amount \$ USD Indefinite

Total Amount Sold \$ USD

Total Remaining to be Sold \$ USD Indefinite

Clarification of Response (if Necessary)

Represents the total exercise prices of warrants to purchase up to 500,000 shares of common stock at an exercise prices of \$0.47 a share.

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

15. Sales Commissions & Finders' Fees Expenses

Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$ USD Estimate

Finders' Fees \$ USD Estimate

Clarification of Response (if Necessary)

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$ USD Estimate

Clarification of Response (if Necessary)

Any proceeds from the exercise of the warrants are expected to be used to augment the issuer's working capital and for general corporate purposes, which could include the payment of compensation to the executive officers and directors of the issuer.

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking **SUBMIT** below to file this notice.

Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Emmaus Life Sciences, Inc.	/s/ Yasushi Nagasaki	Yasushi Nagasaki	Chief Financial Officer	2023-01-31